GOQii, a leading smart preventive healthcare company, and Acrannolife Genomics, a pioneer in precision diagnostics, have partnered to introduce GrafCare, an innovative program poised to transform post-transplant care. This collaboration leverages the power of genomic diagnostics, artificial intelligence (AI), and personalized health monitoring to address the critical needs of organ transplant recipients.

GrafCare offers a comprehensive solution for the healthcare providers seeking to enhance their post-transplant services. By integrating Acrannolife’s patented Trunome test with GOQii’s smart health ecosystem, the program provides early detection of potential complications, real-time health insights, and tailored support, ultimately improving patient outcomes and quality of life.

Key Benefits for the Healthcare Providers:

• Enhanced Patient Care: GrafCare empowers healthcare providers to deliver proactive and personalized post-transplant care, leading to better patient management and satisfaction.
• Early Intervention Capabilities: The Trunome test enables early detection of organ rejection and infection, allowing for timely interventions and potentially preventing serious complications.
• Data-Driven Insights: Real-time health monitoring through the GOQii Smart Vital Device and AI-powered analytics provides valuable data for informed clinical decision-making.
• Improved Efficiency: The program streamlines post-transplant care, potentially reducing the need for reactive interventions and hospital readmissions.
• Comprehensive Program Support: GrafCare offers access to expert coaching and personalized recovery plans, enhancing the overall patient experience.
• Financial Accessibility Options: The program’s focus on financial accessibility, including potential loan options and discounts, can help healthcare providers address patient affordability concerns.

The GrafCare Advantage:

• Trunome Test: This US-patented, non-invasive blood test utilizes advanced genomic research and AI to identify early signs of organ rejection or infection, providing clinicians with actionable insights.
• GOQii Smart Vital Device: This device continuously tracks vital parameters, providing real-time data for AI-driven predictive analytics and personalized recommendations.
• Personalized Care Plans: Nutritionists and counselors develop tailored recovery plans based on individual patient needs and genetic profiles.

Also Read: MedMitra AI Secures ₹3 Crore Funding to Transform Healthcare with AI-Driven Solutions

“GrafCare represents a significant advancement in post-transplant care, offering a proactive and predictive approach that benefits both patients and healthcare providers,” said Vishal Gondal, Founder & CEO, GOQii. “We are excited to partner with Acrannolife Genomics to bring this innovative solution to the healthcare market.”

Agragesh Ramani, Co-founder, Acrannolife Genomics, added, “Our Trunome test, at the heart of the GrafCare program, offers a crucial advantage in early detection of organ rejection. This partnership allows us to provide comprehensive, cutting-edge care to transplant recipients, improving their chances for long-term success.”

GrafCare is poised to redefine the standard of post-transplant care, offering healthcare providers a valuable tool to improve patient outcomes, enhance efficiency, and deliver personalized, data-driven care.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!